While the Enhancing Oncology Model is the successor of the Oncology Care Model, it includes some very real challenges for participating practices, explained Lalan Wilfong, MD, senior vice president of payer and care transformation at The US Oncology Network.
The Enhancing Oncology Model (EOM), the successor of the Oncology Care Model (OCM), is not guaranteed to be a success based on some of the challenges and limitations facing participating practices, said Lalan Wilfong, MD, senior vice president of payer and care transformation at The US Oncology Network.
Several practices under The US Oncology Network umbrella are participating in the EOM.
COA has been outspoken in its criticism of the Center of Medicare and Medicaid Innovation. In what areas can the EOM improve to optimize keeping integrated value-based cancer care in the community and care costs down?
The Enhancing Oncology Model has a lot of good things about it and good things that they are trying to do, such as electronic patient-reported outcomes, and brought to light to social determinants of health and our need to screen and assist patients for that. There are criticisms for the EOM. Some of the main ones include the small MEOS [Monthly Enhanced Oncology Service] payments. It is very challenging to do the work that we need to do with the small amount of money that Medicare is giving us to fund those initiatives.
The small patient population, although it's good in one way that we're focusing on the patients that are at the highest risk, it hurts practices and their ability to have a wide breadth of patients so that we can provide services to all patients, not just those in the model. The other thing that I don't think people talk about as much is the impact on MIPS [Merit-based Incentive Payment System]. With the changing quality thresholds for MIPS, practices in the EOM will not meet thresholds to have success in MIPS with the model the way it is currently designed, which is a true limitation and puts a greatly increased burden on the practices for doing both programs.
Considering what you have seen so far about the EOM, is it indeed a successor model to the OCM?
EOM is definitely a successor to OCM. However, I don't think that means that it will be a success. There are many good qualities about the EOM like I described with the screening for social determinants of health and the focus on electronic patient-reported outcomes. It is challenging, though, to think that this will truly change the needle like OCM did in community oncology practices. Practices, because of the small payments, are going to be forced to only focus on those patients that are in the model. And it won't impart the same changes and all care management that the OCM was able to achieve.
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
OptumRx’s Jon Mahrt Discusses “Irresponsible” Drug Pricing for Products With Multiple Indications
April 30th 2024When the same product comes to market with additional indications, irrational pricing decisions result in ever increasing prices instead of volume translating to lower costs, said Jon Mahrt, MBA, of OptumRX.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
USPSTF Lowers Age for Biennial Mammograms to 40, Citing Early Detection Benefit
April 30th 2024The USPSTF lowered the recommended starting age for mammograms from 50 to 40 years, citing moderate benefits for early detection in this age group. Disparities persist, especially for Black women, highlighting the need for improved access to health care and social support.
Read More
Medicaid, Medicare Policy Changes Could Lead to More Than 25,000 Additional Deaths, Study Says
April 30th 2024Researchers also estimated that more than 700,000 Americans with diabetes could lose insurance coverage if these proposed retractions are put into place, with some new policies already in effect.
Read More